Case Report: Long-term response to camrelizumab in PD-L1-negative/MSS advanced carcinoma ex pleomorphic adenoma of the palate

Carcinoma ex pleomorphic adenoma (CEPA) is an uncommon malignant salivary gland tumor arising from a preexisting pleomorphic adenoma and constitutes roughly 3.6% of all salivary gland neoplasms. We present a 67-year-old female patient diagnosed with CEPA in the palatal region, who received surgical excision followed by postoperative radiotherapy. Local tumor relapse in the palate was detected at the 4-year follow-up. Radical radiotherapy was administered concurrently with cisplatin monotherapy. Nevertheless, no significant tumor shrinkage was observed after radical chemoradiotherapy. The treatment regimen was subsequently modified to maintenance monotherapy with camrelizumab. The palatal mass showed continuous regression, and the patient remained clinically stable with ongoing long-term multidisciplinary surveillance. Camrelizumab was initiated on August 2, 2021, and the patient remained progression-free at the last follow-up in March 2025, corresponding to a progression-free survival of approximately 43 months. Despite programmed death ligand 1 (PD-L1) negativity (0% tumor cell staining) and microsatellite-stable (MSS) phenotype, the patient achieved durable remission. To our knowledge, this case is among the earliest reports confirming the clinical efficacy of immune checkpoint inhibitors (ICIs) in recurrent CEPA of the palate. Our findings suggest that ICIs can serve as a feasible systemic alternative option for patients with postoperative recurrence of palatal CEPA.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1901602
Primary Topic
Salivary Gland Tumors Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Long-term response to camrelizumab in PD-L1-negative/MSS advanced carcinoma ex pleomorphic adenoma of the palate

姜沁延, Jie Wang
Frontiers in Oncology
Salivary Gland Tumors Diagnosis and Treatment
article

Case Report: Long-term response to camrelizumab in PD-L1-negative/MSS advanced carcinoma ex pleomorphic adenoma of the palate

姜沁延, Jie Wang
article en

Abstract

Carcinoma ex pleomorphic adenoma (CEPA) is an uncommon malignant salivary gland tumor arising from a preexisting pleomorphic adenoma and constitutes roughly 3.6% of all salivary gland neoplasms. We present a 67-year-old female patient diagnosed with CEPA in the palatal region, who received surgical excision followed by postoperative radiotherapy. Local tumor relapse in the palate was detected at the 4-year follow-up. Radical radiotherapy was administered concurrently with cisplatin monotherapy. Nevertheless, no significant tumor shrinkage was observed after radical chemoradiotherapy. The treatment regimen was subsequently modified to maintenance monotherapy with camrelizumab. The palatal mass showed continuous regression, and the patient remained clinically stable with ongoing long-term multidisciplinary surveillance. Camrelizumab was initiated on August 2, 2021, and the patient remained progression-free at the last follow-up in March 2025, corresponding to a progression-free survival of approximately 43 months. Despite programmed death ligand 1 (PD-L1) negativity (0% tumor cell staining) and microsatellite-stable (MSS) phenotype, the patient achieved durable remission. To our knowledge, this case is among the earliest reports confirming the clinical efficacy of immune checkpoint inhibitors (ICIs) in recurrent CEPA of the palate. Our findings suggest that ICIs can serve as a feasible systemic alternative option for patients with postoperative recurrence of palatal CEPA.

Frontiers in OncologyVol. 16
Dalian Municipal Central Hospital (CN)
Good health and well-being
Salivary Gland Tumors Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon